A5054730003- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- Viral-associated cancers and disorders
- Protein Degradation and Inhibitors
- CNS Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Histone Deacetylase Inhibitors Research
- Peptidase Inhibition and Analysis
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
- Cutaneous lymphoproliferative disorders research
- Medical Imaging Techniques and Applications
- Lipid metabolism and disorders
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Galectins and Cancer Biology
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- HIV/AIDS drug development and treatment
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
2019-2025
The Ohio State University
2016-2025
The Ohio State University Wexner Medical Center
2015-2024
Ohio University
2010-2013
University of Bologna
2002-2009
Policlinico S.Orsola-Malpighi
2003-2009
Université Paris Cité
2007
Hôtel-Dieu de Paris
2007
Ospedale Bellaria
2007
Istituto di Ematologia di Bologna
2007
To determine the antitumor activity of proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral unspecified (PTCLU) isolated skin involvement.From May 2005 to June 2006 at our institute, we treated previously pretreated CTCL PTCLU using as a single agent, dose 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 for total six cycles.Fifteen were registered, whom 12 (10 CTCL, all mycosis fungoides, two involvement) assessable. The overall response...
Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary with few and conflicting data on their prognostic factors.The study included 467 patients PCBCL who were referred, treated, observed in 11 Italian centers (the Study Group for Cutaneous Lymphomas) during 24-year period (1980 to 2003). All the reclassified according WHO-European Organisation Research Treatment Cancer (EORTC) classification.Follicle center lymphoma (FCL) accounted 56.7% occurrences, followed by...
Purpose In lymphoma, [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) is routinely used for initial staging, early evaluation of treatment response, and identification disease relapse. However, there are no prospective studies investigating the value serial FDG-PET over time in patients complete remission. Patients Methods All with lymphoma who achieved first remission were prospectively enrolled onto study scheduled scans at 6, 12, 18, 24 months; further then carried out on...
Abstract Glioblastoma is the most common and aggressive histologic subtype of brain cancer with poor outcomes limited treatment options. Here, we report selective overexpression protein arginine methyltransferase PRMT5 as a novel candidate theranostic target in this disease. silences transcription regulatory genes by catalyzing symmetric dimethylation residues on histone tails. patient-derived primary tumors cell lines correlated line growth rate inversely overall patient survival. Genetic...
Bromodomain and extra-terminal (BET) family proteins are key regulators of gene expression in cancer. Herein, we utilize BRD4 profiling to identify critical pathways involved pathogenesis chronic lymphocytic leukemia (CLL). is overexpressed CLL enriched proximal genes upregulated or de novo expressed with known functions disease progression. These genes, including members the B-cell receptor (BCR) signaling pathway, provide a rationale for this therapeutic approach new targets alternative...
Based on the activity of gemcitabine in heavily pretreated patients with cutaneous T-cell lymphoma (CTCL), objective current study was to determine role treatment advanced, untreated CTCL.Between June 2002 and February 2004, 32 mycosis fungoides (MF) (n = 26 patients); peripheral lymphoma, unspecified (PTCLU) exclusive skin involvement 5 Sezary syndrome (SS) 1 patient) were enrolled a 7-institution, Phase II trial treated gemcitabine. This drug given Days 1, 8, 15 28-day schedule at dose...
Promising new therapeutic options for follicular lymphoma (FL) include fludarabine plus mitoxantrone (FM) and the mouse/human anti-CD20 antibody, rituximab. We performed a randomized comparative trial of FM with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) front-line chemotherapy without sequential rituximab.All previously untreated CD20(+) FL patients presenting in 15 Italian cooperative institutions from October 1999 were randomly allocated to or CHOP. Following clinical...
An extensive analysis of the reliability positron emission tomography (PET) after induction treatment in patients with Hodgkin's disease (HD) or aggressive non-Hodgkin's lymphoma (NHL). In all, 75 untreated HD (n=41) NHL (n=34) were studied both PET and CT scans following standard chemotherapy therapy (ABVD MACOP-B) with/without radiotherapy. Histopathological was performed when considered necessary. After treatment, four out five (80%) who PET+/CT− relapsed, as compared zero 29 PET−/CT−...
Objective To evaluate the prevalence and scan interpretation criteria useful in identifying non-tumoural 18F-FDG focal uptakes (potential pitfalls) patients who had been previously treated for a malignant lymphoma studied by positron emission tomography (PET). Materials Nine hundred ninety-six consecutive PET scans obtained 706 with were reviewed. All first-line chemo-radiotherapy, plus surgery when required, then FDG to investigate suspected recurrence at doubtful or inconclusive...
Background and Objectives Follow-ups of patients with mediastinal lymphoma are not accurate if they rely on computed tomography (CT). Positron emission (PET) has been suggested to be useful in several settings, such as initial staging, evaluation residual masses after therapy, assessment response early the course treatment. The aim this retrospective study was verify reliability positive PET scans mediastinum following up wirh lymphoma, using histological findings a comparison.Design Methods...
De novo CD5+ diffuse large B-cell lymphomas (DLBCL) are a distinct subgroup of DLBCL with poor prognosis. However the role rituximab-containing therapy and salvage stem cell transplantation in this patients' population remain to be defined. We retrospectively reviewed clinical features outcomes 102 patients de treated at nine different institutions. By Hans' criteria, 64 had activated (ABC) subtype, 24 germinal center (GCB) 14 were not evaluated. No myc translocation. Eighty-three rituximab,...
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor complex (P-TEFb), a heterodimeric protein composed of cyclin dependent 9 (CDK9) T1, functions to regulate short half-life transcripts by phosphorylation RNA Polymerase II (POLII). These frequently dysregulated in hematologic malignancies;...
Abstract Richter’s Transformation (RT) is a poorly understood and fatal progression of chronic lymphocytic leukemia (CLL) manifesting histologically as diffuse large B-cell lymphoma. Protein arginine methyltransferase 5 (PRMT5) implicated in lymphomagenesis, but its role CLL or RT unknown. We demonstrate herein that tumors uniformly overexpress PRMT5 patients with to RT. Furthermore, mice B-specific overexpression hPRMT5 develop B-lymphoid expansion increased risk death, Eµ-PRMT5/TCL1 double...
Abstract BACKGROUND Mucosa‐associated lymphoid tissue (MALT) lymphoma is a specific clinicopathologic entity with gastric and nongastrointestinal site involvement. The authors reported the clinical outcome of patients Stage IE MALT treated frontline fludarabine‐containing regimen or containing cyclophosphamide, vincristine, prednisone (CVP). METHODS Between 1998 2001, 31 disease were referred to Seràgnoli Institute Hematology Medical Oncology at University Bologna (Bologna, Italy)....
Abstract BACKGROUND. Limited data exist about the role of second‐line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non‐Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT). The objective this analysis was to investigate main determinants prognosis B‐cell NHL ASCT, focusing on impact pretransplantation PET, secondary age‐adjusted International Prognostic Index (sAA‐IPI) score, histology, and...